Mekinist(trametinib)
Mekinist, Trametinib Dimethyl Sulfoxide (trametinib) is a small molecule pharmaceutical. Trametinib was first approved as Mekinist on 2013-05-29. It is used to treat melanoma and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Mekinist (discontinued: Mekinist, Trametinib dimethyl sulfoxide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mekinist | New Drug Application | 2025-03-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-small-cell lung carcinoma | — | D002289 | — |
| melanoma | — | D008545 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRAMETINIB DIMETHYL SULFOXIDE, MEKINIST, NOVARTIS | |||
| 2030-03-16 | ODE-428 | ||
| 2026-03-16 | I-908, NP | ||
| 2025-12-22 | PED | ||
| 2025-11-04 | PED | ||
| 2025-10-30 | PED | ||
| 2025-06-22 | I-895 | ||
| 2025-05-04 | ODE-183 | ||
| 2025-04-30 | ODE-182 | ||
| 2024-12-22 | PED | ||
| 2024-06-22 | ODE-148 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Trametinib Dimethyl Sulfoxide, Mekinist, Novartis | |||
| 10869869 | 2033-08-30 | U-3184 | |
| 8580304 | 2032-01-28 | DP | |
| 9155706 | 2032-01-28 | DP | |
| 9271941 | 2032-01-28 | DP | |
| 9399021 | 2032-01-28 | DP | |
| 8703781 | 2030-10-15 | DS, DP | U-1712, U-2020, U-2037, U-2302, U-2305, U-3564 |
| 8952018 | 2030-10-15 | U-2020 | |
| 7378423 | 2027-05-29 | DS, DP | |
| 8835443 | 2025-06-10 | U-1581, U-1582, U-2020, U-2037, U-2302, U-2305, U-3564 | |
HCPCS
No data
Clinical
Clinical Trials
285 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 6 | 9 | 5 | 1 | 12 | 30 |
| Neoplasms | D009369 | — | C80 | 13 | 15 | — | 1 | 1 | 24 |
| Non-small-cell lung carcinoma | D002289 | — | — | 7 | 6 | — | 1 | 2 | 14 |
| Lung neoplasms | D008175 | — | C34.90 | 7 | 6 | — | 1 | 2 | 13 |
| Glioma | D005910 | EFO_0000520 | — | 2 | 1 | — | 1 | — | 4 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | 1 | — | 3 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | 1 | — | 1 | — | 3 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | 1 | — | 1 | — | 3 |
| Ganglioglioma | D018303 | — | — | 1 | 1 | — | 1 | — | 3 |
| Neurofibromatoses | D017253 | — | Q85.00 | 1 | 2 | — | 1 | — | 3 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 1 | 1 | — | — | 4 |
| Thyroid diseases | D013959 | — | E00-E07 | 2 | 1 | 1 | — | — | 4 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | 1 | 1 | — | — | 2 |
| Fever | D005334 | — | R50.9 | — | — | 1 | — | — | 1 |
| Hyperthermia | D000084462 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 7 | 5 | — | — | — | 9 |
| Carcinoma | D002277 | — | C80.0 | 3 | 2 | — | — | 1 | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 2 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 3 | — | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | 1 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 3 |
| Adamantinoma | D050398 | — | — | — | 2 | — | — | — | 2 |
| Plexiform neurofibroma | D018318 | EFO_0000658 | — | 1 | 2 | — | — | — | 2 |
| Neurofibroma | D009455 | EFO_0000622 | — | 1 | 2 | — | — | — | 2 |
| Anaplastic thyroid carcinoma | D065646 | — | — | 1 | 1 | — | — | — | 2 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 2 | — | — | — | 1 | 3 |
| Adenocarcinoma | D000230 | — | — | 2 | — | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 1 | — | — | — | — | 1 |
| Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
| Rhabdoid tumor | D018335 | — | — | 1 | — | — | — | — | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | — | — | — | — | 1 |
Show 15 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trametinib |
| INN | trametinib |
| Description | Trametinib is a pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent, an anticoronaviral agent and a geroprotector. It is a pyridopyrimidine, an organofluorine compound, an organoiodine compound, a member of acetamides, a ring assembly, a member of cyclopropanes and an aromatic amine. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1 |
Identifiers
| PDB | — |
| CAS-ID | 871700-17-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103875 |
| ChEBI ID | 75998 |
| PubChem CID | 11707110 |
| DrugBank | DB08911 |
| UNII ID | 33E86K87QN (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (P28028)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,006 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,204 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use